In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J gets rights to Vertex's VX950 for HCV; Janssen buys royalty rights

Executive Summary

Johnson & Johnson's Tibotec Pharmaceuticals (focused on the development of anti-infective therapeutics) and Janssen Pharmaceutica NV divisions have signed on to develop and market Vertex Pharmaceuticals's VX950, an investigational oral hepatitis C virus (HCV) protease inhibitor. The exclusive agreement covers Europe, South America, the Middle East, Africa, and Australia. Vertex keeps exclusive marketing rights in North America.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register